Scientists create mouse model to accelerate research on Ebola vaccines, treatments

October 31, 2014 by Mark Derewicz, University of North Carolina at Chapel Hill School of Medicine
Ebola virus. Credit: CDC

In the war against Ebola, one important hurdle has just been cleared – by a mouse.

A study published in the latest issue of Science details how researchers from UNC and their colleagues at NIH Rocky Mountain National Laboratory and the University of Washington have developed a new genetic strain of mice that will significantly improve opportunities to test the initial efficacy of potential vaccines and treatments for Ebola and other emerging pathogens.

The study, titled "Host enables Ebola hemorrhagic fever pathogenesis and resistance," describes how these researchers solved an important challenge facing any scientific team seeking remedies to Ebola.

Mouse lines traditionally used for pharmacological and medical research do not develop human-like Ebola disease, including the severe symptoms that can prove fatal in humans. The study's co-authors were able to breed together genetic mouse variants and successfully test a strain of mice to permit active research on potential Ebola vaccines and treatments in model systems that more accurately reflect the human condition.

William Fischer II, MD, an assistant professor of medicine who has treated Ebola patients in Africa, said, "A basic understanding of how our genetics influence susceptibility to viral infections and affect disease development is absolutely critical to creating much needed therapeutic interventions." Fischer, who was not part of this research project, added, "We can decrease Ebola fatality rates with intensive critical care but this is difficult to do in places with limited human and material resources. Rationally designed treatments and vaccines are desperately needed."

Science paper co-author, Martin Ferris, PhD, a research assistant professor of genetics in the UNC School of Medicine, said, "Public perception of Ebola infection typically focuses on the high mortality rate following hemorrhagic fever, but Ebola actually produces a range of disease symptoms. During an outbreak, it is often difficult to assess the role that plays in determining disease severity in people. And if we're going to develop treatments, then we need to know about this genetic variation."

Ferris and colleagues bred and tested different mouse strains from the "Collaborative Cross" for susceptibility to Ebola. The Collaborative Cross, which is housed at and distributed by UNC, is a population of genetically diverse mice that was developed by five institutions, including UNC, so that researchers can assess the role of genetic variation in a wide spectrum of medically relevant phenotypes – observable physical and biochemical characteristics and traits of an organism.

"Since the Collaborative Cross was designed to better model human genetic diversity, it has proven to be a powerful system for studying how genetic variation affects susceptibility to a number of emerging pathogens, including Ebola virus," said study co-author Mark Heise, PhD, professor of genetics at the UNC School of Medicine.

These studies, which were conducted at the NIH Rocky Mountain National Laboratory, demonstrated that the genetic variation of the mice directly led to different disease responses after infection. Importantly, these research groups were able to identify variation within a specific gene that controlled much of the variation in disease severity between individual mice. Because this gene also is variable within the human population, the results of this research point to a potential target for therapeutics in combating Ebola in people.

"In essence, we were able to produce a novel platform for rapidly developing new mouse models that replicate human disease outcomes when infected with Ebola as well as other important emerging human pathogens in the future," said study co-author Ralph Baric, PhD, professor of epidemiology at the UNC Gillings School of Global Public Health. "This could accelerate and improve studies on potential vaccines or treatments while lowering overall costs."

This work is part of a larger collaboration between the UNC Department of Genetics, the UNC Gillings School of Global Public Health, University of Washington Department of Microbiology, NIH Rocky Mountain National Laboratories, and the Oregon Health Sciences University to understand how genetic variation affects susceptibility to a range of viral diseases.

Explore further: Genetic factors behind surviving or dying from Ebola shown in mouse study

More information: "Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance." Science DOI: 10.1126/science.1259595 Published Online October 30 2014

Related Stories

Doctor exposed to Ebola treated in US

September 29, 2014

An American doctor who was exposed to the Ebola virus in Sierra Leone was admitted Sunday to a clinic of the National Institutes of Health outside Washington.

Study: Young people more likely to survive Ebola

October 29, 2014

A new study gives fresh knowledge about who survives Ebola and why. The report by 47 health workers treating patients in Sierra Leone in West Africa is the most detailed description yet of the medical aspects of the current ...

American doctor exposed to Ebola allowed home

October 8, 2014

An American physician who was hospitalized in the United States after being exposed to the Ebola virus in Sierra Leone was allowed home Tuesday, health officials said.

Recommended for you

Physicists reveal why matter dominates universe

March 21, 2019

Physicists in the College of Arts and Sciences at Syracuse University have confirmed that matter and antimatter decay differently for elementary particles containing charmed quarks.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.